Literature DB >> 6640871

Cardiovascular manifestations of mixed connective tissue disease in adults.

M A Alpert, S H Goldberg, B H Singsen, J B Durham, G C Sharp, M Ahmad, N P Madigan, D P Hurst, W D Sullivan.   

Abstract

To assess the nature and distribution of cardiovascular abnormalities associated with mixed connective tissue disease, we studied 38 patients with overlapping clinical manifestations of systemic lupus erythematosus, progressive systemic sclerosis and polymyositis, and circulating antibodies to nuclear ribonucleoprotein. The protocol included taking a medical history and a physical echocardiogram, and pulmonary function tests. Cardiac catheterization was performed on 17 patients. Postmortem examination was performed on four of the five patients who died during follow-up. Acute pericarditis and/or pericardial effusion was detected in 11 patients (29%) and mitral valve prolapse was identified in 10 patients (26%). Marked intimal hyperplasia of coronary arteries was observed in all four hearts that were autopsied and perivascular and myocardial leukocytic aggregates were present in two hearts. Pulmonary vascular resistance was elevated in 11 of the 17 patients who underwent cardiac catheterization. In summary, cardiovascular abnormalities associated with mixed connective tissue disease include acute pericarditis and/or effusion, mitral valve prolapse, intimal hyperplasia of coronary arteries, perivascular and myocardial leukocytic infiltrates, and pulmonary hypertension.

Entities:  

Mesh:

Year:  1983        PMID: 6640871     DOI: 10.1161/01.cir.68.6.1182

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  18 in total

Review 1.  Treatment of pulmonary hypertension secondary to connective tissue diseases.

Authors:  O Sanchez; M Humbert; O Sitbon; G Simonneau
Journal:  Thorax       Date:  1999-03       Impact factor: 9.139

2.  Diastolic function of the heart in mixed connective tissue disease.

Authors:  Judit Végh; Ida Hegedus; Gyula Szegedi; Margit Zeher; Edit Bodolay
Journal:  Clin Rheumatol       Date:  2006-07-25       Impact factor: 2.980

Review 3.  Mixed connective tissue disease, overlap syndromes, and eosinophilic fasciitis.

Authors:  P J Maddison
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

4.  Pulmonary hypertension in connective tissue disease. Clinical analysis of sixty patients in multi-institutional study.

Authors:  R Kasukawa; T Nishimaki; T Takagi; S Miyawaki; R Yokohari; T Tsunematsu
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

Review 5.  Cardiac involvement in systemic autoimmune diseases.

Authors:  Piersandro Riboldi; Maria Gerosa; Cristina Luzzana; Luca Catelli
Journal:  Clin Rev Allergy Immunol       Date:  2002-12       Impact factor: 8.667

6.  Pulmonary arterial hypertension in mixed connective tissue disease: successful treatment with Iloprost.

Authors:  Judit Végh; Györgyike Soós; István Csipõ; Nóra Demeter; Thomas Ben; Balázs Dezsõ; Margit Zeher; Katalin Dévényi; János Gaál; Gyula Szegedi; Edit Bodolay
Journal:  Rheumatol Int       Date:  2005-07-12       Impact factor: 2.631

7.  Pulmonary hypertension in MCTD: report of two cases with anticardiolipin antibody.

Authors:  M Miyata; S Kida; T Kanno; K Suzuki; H Watanabe; S Kaise; T Nishimaki; Y Hosoda; R Kasukawa
Journal:  Clin Rheumatol       Date:  1992-06       Impact factor: 2.980

Review 8.  Pulmonary hypertension in rheumatic diseases: epidemiology and pathogenesis.

Authors:  Anupama Shahane
Journal:  Rheumatol Int       Date:  2013-01-19       Impact factor: 2.631

9.  Echocardiographic findings in patients with primary Sjögren's syndrome.

Authors:  S Rantapää-Dahlqvist; C Backman; H Sandgren; Y Ostberg
Journal:  Clin Rheumatol       Date:  1993-06       Impact factor: 2.980

10.  Pulmonary hypertension can be a sequela of prior Pneumocystis pneumonia.

Authors:  Steve D Swain; Soo Han; Ann Harmsen; Katie Shampeny; Allen G Harmsen
Journal:  Am J Pathol       Date:  2007-07-19       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.